Summary
35 / 100 · Bulios Score
What speaks for it
- It has been profitable 6 years in a row.
- It passes 8 of the 9 points of the Piotroski financial health test.
What to watch
- Earnings per share fell by 39% a year over the last 3 years.
- The share price is above the Bulios Fair Price.
- It missed profit estimates 8 times in the last 8 quarters.
- Repaying its net debt would take 3.6 years of operating profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 87.1 EUR for 1 EUR of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 8.7% a year over 5 years. Over the last 3 years it fell by 5.4% a year. For the next fiscal year analysts expect revenue to grow by 4.9%. Earnings per share fell by 39% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 EUR of revenue goes
- Cost of sales 54 EUR
- Research and development 5.0 EUR
- Sales and administration 23 EUR
- Taxes and other 12 EUR
- Net profit 5.5 EUR
Net profit, industry median (Medical - Instruments & Supplies) 8.5 EUR
Out of every 100 EUR of revenue, 5.5 EUR is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 13.8 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.31%
- Paid out of profit
- 27%
- Raised in a row
- 1 year
You receive $0.85 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 0
- Sell 0
No analyst has published a price target.
100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.